SITC Archive Library

SITC 31st Annual Meeting (2016): Update Session: Cancer Immunotherapy Trials Network (CITN): Ten Trials with High Priority Agents in Twenty Five Minutes 

03-02-2017 17:06

The Society for Immunotherapy of Cancer (SITC) hosted the "Update Session: Cancer Immunotherapy Trials Network (CITN): Ten Trials with High Priority Agents in Twenty Five Minutes" during the SITC 31st Annual Meeting & Associated Programs on November 11-13, 2016. Available here is the video from the session.

Session Chair

  • Mac Cheever, MD – Fred Hutchinson Cancer Research Center

SITC 31st Annual Meeting Organizers
  • Chair: Lisa H. Butterfield, PhD – University of Pittsburgh
  • James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
  • Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute
  • Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
  • Holbrook E. Kohrt, MD, PhD – Stanford Cancer Institute

About the SITC 31st Annual Meeting

SITC's 31st Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important Society projects. Following SITC’s tradition of collaborating to advance the field, the 31st Annual Meeting featured numerous sessions collaboratively-developed with reputable organizations whose missions complement and align with that of SITC’s. An in-depth Value of Cancer Immunotherapy Summit, organized in collaboration with the American Society of Clinical Oncology, was prominently featured to discuss a crucial topic that impacts all cancer immunotherapy constituents, from researchers and clinicians to payers and cancer patients.

Intended Audience

The intended audience for this program includes U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, scroll down to view Related Entries and Links.


0 Favorited
1 Files
mp4 file
"IDO Inhibitor in Ovarian Cancer and Melanoma" - Video   63.11 MB   1 version
Uploaded - 03-02-2017
Meeting: SITC 31st Annual Meeting; Update Session: Cancer Immunotherapy Trials Network (CITN): Ten Trials with High Priority Agents in Twenty Five Minutes; Presenter: Kunle Odunsi, MD, PhD – Roswell Park Cancer Institute Center for Immunotherapy; Date: November 11, 2016